Antibody buffering of a ligand in vivo

por O'Hear, Carol E., Foote, Jefferson
Publicado 2005

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia

por O’Hear, Carol, Heiber, Joshua F., Schubert, Ingo, Fey, Georg, Geiger, Terrence L.
Publicado en Haematologica (2015)

Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab

por Molinero, Luciana, Li, Yijin, Chang, Ching-Wei, Maund, Sophia, Berg, Maureen, Harrison, Jeanne, Fassò, Marcella, O’Hear, Carol, Hegde, Priti, Emens, Leisha A.
Publicado en J Immunother Cancer (2019)

PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells

por Zheng, Wenting, O’Hear, Carol E., Alli, Rajshekhar, Basham, Jacob H., Abdelsamed, Hosaam, Palmer, Lance E., Jones, Lindsay L., Youngblood, Ben, Geiger, Terrence L.
Publicado en Leukemia (2018)

Gemtuzumab Ozogamicin Can Reduce Minimal Residual Disease in Patients With Childhood Acute Myeloid Leukemia

por O’Hear, Carol, Inaba, Hiroto, Pounds, Stanley, Shi, Lei, Dahl, Gary, Bowman, W. Paul, Taub, Jeffrey W., Pui, Ching-Hon, Ribeiro, Raul C., Coustan-Smith, Elaine, Campana, Dario, Rubnitz, Jeffrey E.
Publicado en Cancer (2013)

Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis

por Emens, Leisha A., Davis, S. Lindsey, Oliver, Scott C. N., Lieu, Christopher H., Reddy, Ashvini, Solomon, Sharon, He, Lingmin, Morley, Roland, Fassò, Marcella, Pirzkall, Andrea, Patel, Hina, O’Hear, Carol, Ferrara, Daniela
Publicado en JAMA Ophthalmol (2018)

Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study

por Petrylak, Daniel P., Powles, Thomas, Bellmunt, Joaquim, Braiteh, Fadi, Loriot, Yohann, Morales-Barrera, Rafael, Burris, Howard A., Kim, Joseph W., Ding, Beiying, Kaiser, Constanze, Fassò, Marcella, O’Hear, Carol, Vogelzang, Nicholas J.
Publicado en JAMA Oncol (2018)

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)

por Powles, Thomas, Nickles, Dorothee, Van Allen, Eliezer, Chappey, Colombe, Zou, Wei, Kowanetz, Marcin, Kadel, Edward, Denker, Mitchell, Boyd, Zachary, Vogelzang, Nicholas, Kim, Joseph, Bellmunt, Joaquim, Loriot, Yohann, Drake, Charles G, O'Hear, Carol, Fasso, Marcella, Hegde, Priti, Mariathasan, Sanjeev
Publicado en J Immunother Cancer (2015)

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study

por Emens, Leisha A., Cruz, Cristina, Eder, Joseph Paul, Braiteh, Fadi, Chung, Cathie, Tolaney, Sara M., Kuter, Irene, Nanda, Rita, Cassier, Philippe A., Delord, Jean-Pierre, Gordon, Michael S., ElGabry, Ehab, Chang, Ching-Wei, Sarkar, Indrani, Grossman, William, O’Hear, Carol, Fassò, Marcella, Molinero, Luciana, Schmid, Peter
Publicado en JAMA Oncol (2018)